A Clinical Study to Assess the Effect of Vildagliptin on Postprandial Lipid Parameters in Patients With Type 2 Diabetes
Phase of Trial: Phase II
Latest Information Update: 17 Oct 2012
At a glance
- Drugs Vildagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Novartis Pharmaceuticals
- 17 Oct 2012 Placebo added as control group and multiple endpoints and inclusion/exclusion data added for the sub-study details.
- 05 Oct 2012 Results of the sub-study analysis presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
- 09 May 2012 New trial record